Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be
PLEASANTON, Calif., Dec. 10, 2012
PLEASANTON, Calif., Dec. 10, 2012 /PRNewswire/ -- Thoratec Corporation
(NASDAQ: THOR), a world leader in device-based mechanical circulatory support
therapies to save, support and restore failing hearts, said today it will be
participating in the Oppenheimer 23^rd Annual Healthcare Conference on
Wednesday, December 12.
Taylor C. Harris, Vice President and Chief Financial Officer, will provide an
update on the company beginning at 10:35 a.m., Eastern Standard Time (7:35
a.m., Pacific Standard Time). The presentation will be available through the
conference website at
http://www.veracast.com/webcasts/opco/healthcare2012/57106258.cfmor on the
company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart
failure. The company's products include the HeartMate® LVAS (Left Ventricular
Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than
20,000 devices implanted in patients suffering from heart failure. Thoratec
also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product
lines. Thoratec is headquartered in Pleasanton, California. For more
information, visit the company's website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered
trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec
Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC,
and PediVAS is a registered trademark of Thoratec Switzerland GmbH.
SOURCE Thoratec Corporation
Contact: Taylor Harris, Vice President and Chief Financial Officer, Thoratec
Press spacebar to pause and continue. Press esc to stop.